TAG:
impath inc
Welsh Carson Pays $1.14 Billion To Acquire U.S. Oncology, Inc.
By Robert Michel | From the Volume XI No. 5 – April 5, 2004 Issue
EVEN AS THE LAST ISSUE of THE DARK REPORT was reaching clients with news of Genzyme Corp.’s offer to buy IMPATH Inc., another big oncology deal was announced. On March 22, 2004, Welsh, Carson, Anderson & Stowe announced an offer of $15.05 per …
Chapter 11 Bankruptcy Filed by IMPATH, Inc.
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
CEO SUMMARY: To the surprise of very few, IMPATH, Inc. filed for Chapter 11 bankruptcy protection. During 2003, most of IMPATH’s key executives departed as different problems within the company became known. IMPATH’s new executive leadership is dealing with a host of difficult issues….
Dynacare, LabCorp, IMPATH, Visible Genetics, Abbott Labs
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
ACTIVITY AT DYNACARE HINTS AT POSSIBLE SALE, LABCORP MAY BE BUYER With Quest Diagnostics Incorporated snapping up independent lab companies right and left in recent months, the question asked by many is “Where’s Laboratory Corporation of America?†On …
Park City Solutions, DIANON, IMPATH American Med Labs, Cytyc, TriPath Imaging
By Robert Michel | From the Volume VII No. 4 – March 6, 2000 Issue
PARK CITY SOLUTIONS AND AMERICAN MEDICAL LABS CREATE STRATEGIC PACT TWO COMPANIES FINANCED by GTCR Golder Rauner, LLC, the private equity firm based in Chicago, announced a strategic relationship. Park City Solutions, Inc. of Park City, Utah and Ame…
Developing Technology Expected To Fuel Boom In Anatomic Pathology
By Robert Michel | From the Volume VI No. 8 – June 7, 1999 Issue
CEO SUMMARY: Established demographic trends point to a coming boom in the demand for anatomic pathology services. Greater number s of senior citizens, living longer lives, will raise the number of cancer cases diagnosed annually in the United States. New diagnostic technology will increas…
“Value Added†Services Essential to Success
By R. Lewis Dark | From the Volume VI No. 2 – February 1, 1999 Issue
ONE ELEMENT COMMON TO SUCCESSFUL LABORATORY ORGANIZATIONS of the future will be the ability to both understand the concept of “value added†services and to offer such services to customers. At its core, value added is an essential business strategy. There are many ways to define “value added.â…
IMPATH Creates Its Brand Of Value-Added Pathology
By Robert Michel | From the Volume VI No. 2 – February 1, 1999 Issue
CEO SUMMARY: IMPATH Inc. is a pathology company with an interesting twist. It doesn’t compete directly with community hospital-based pathologists like some national AP providers. Instead, it offers AP services which supplement the capabilities of the local pathologist. The formula must …
IMPATH Points Pathology Toward a Winning Future
By Robert Michel | From the Volume VI No. 2 – February 1, 1999 Issue
CEO SUMMARY: Pathology is about to undergo a market transformation similar to radiology. As clinicians insist on more precise diagnostic and prognostic information about their patients, pathologists will have a perfect opportunity to reposition themselves as essential partners with the re…
“Disease Management†Firms, Niche Labs Release Financials
By Robert Michel | From the Volume V No. 8 – June 15, 1998 Issue
Two DISEASE MANAGEMENT FIRMS enjoyed strong revenue growth during the first quarter of 1998. UroCor, Inc. and Impath Inc. posted revenue increases of 31% and 49%, respectively, over first quarter 1997. UroCor is the disease management company which serves urologists…
“March 23, 1998 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume V No. 4 – March 23, 1998 Issue
Independent physician association (IPA) executives gathered in Orlando two weeks ago for the annual meeting of TIPAAA, The IPA Association of America. Because IPAs play an increasing role in contracting for laboratory services, THE DARK REPORT was in attendance to learn more about th…
CURRENT ISSUE
Volume XXXII, No. 1 – January 6, 2025
The Dark Report examines how AI is being used to predict the outcomes of FDA LDT lawsuits. Also, this issue is Part Two of a series about boosting pathology compensation in different settings, including hospitals. Two experienced pathology consultants identify the most effective approaches when negotiating Part A pathology agreements with hospitals and health systems, along with how to use data to bolster these negotiations.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized
The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103
Email: info@darkreport.com
© 2025 The Dark Report. All rights reserved.